BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34410469)

  • 1. A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.
    Xiao L; Kang W; Liao J; Li Y
    Eur Arch Otorhinolaryngol; 2022 May; 279(5):2441-2450. PubMed ID: 34410469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Tang M; Jia Z; Zhang J
    Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1561-1572. PubMed ID: 34259896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
    Zang J; Xu M; Li C; Zhao L; Luo S; Wang J; Shi M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2369-2378. PubMed ID: 32363479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies.
    Chan SK; Chan SY; Tong CC; Lam KO; Kwong DL; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
    Oral Oncol; 2021 Mar; 114():105158. PubMed ID: 33508707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
    Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
    Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
    Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials.
    Wang P; Zhang M; Ke C; Cai C
    Medicine (Baltimore); 2020 Mar; 99(10):e19360. PubMed ID: 32150078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
    Fei Q; Chen HB; Zhang CM; Xu JJ; He X; Chen SW
    Medicine (Baltimore); 2021 Apr; 100(14):e25398. PubMed ID: 33832134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
    Kong XY; Lu JX; Yu XW; Zhang J; Xu QL; Zhang RJ; Mi JL; Liao SF; Fan JF; Qin XL; Yao DC; Tang HY; Jiang W
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):155-161. PubMed ID: 31087135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
    Zhang Y; Chen L; Hu GQ; Zhang N; Zhu XD; Yang KY; Jin F; Shi M; Chen YP; Hu WH; Cheng ZB; Wang SY; Tian Y; Wang XC; Sun Y; Li JG; Li WF; Li YH; Tang LL; Mao YP; Zhou GQ; Sun R; Liu X; Guo R; Long GX; Liang SQ; Li L; Huang J; Long JH; Zang J; Liu QD; Zou L; Su QF; Zheng BM; Xiao Y; Guo Y; Han F; Mo HY; Lv JW; Du XJ; Xu C; Liu N; Li YQ; Chua MLK; Xie FY; Sun Y; Ma J
    N Engl J Med; 2019 Sep; 381(12):1124-1135. PubMed ID: 31150573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis.
    Wu Q; Li S; Liu J; Zhong Y
    Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5057-5069. PubMed ID: 35767064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
    Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.
    Zhang Y; Sun Y; Ma J
    Cancer Commun (Lond); 2019 Jun; 39(1):39. PubMed ID: 31238975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.
    Zheng L; Liao W; Xu P; Li B; Wen H; Zhang S
    Med Sci Monit; 2018 Nov; 24():8001-8008. PubMed ID: 30406770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
    Gu MF; Liu LZ; He LJ; Yuan WX; Zhang R; Luo GY; Xu GL; Zhang HM; Yan CX; Li JJ
    Int J Cancer; 2013 Jan; 132(1):215-23. PubMed ID: 22610788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.